The Lancet Haematology

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

The Lancet Haematology
Feb 7, 2025, 19:19 | Blog
The Lancet Haematology's February Issue is Live
The Lancet Haematology posted on LinkedIn: "February Issue Now Live! This month, our editorial underscores…
Nov 12, 2024, 08:27 | Insight
Decitabine, venetoclax and ponatinib for advanced phase CML and Philadelphia chromosome-positive AML
Benlazar S M A, Professor of hematology, Universitary hospital of Sidi Bel Abbés, shared an…
Sep 25, 2024, 14:36 | Blog
Fadi Haddad: DAC-VEN-PONATINIB in CML MBP by Nicholas Short
Fadi Haddad posted on X: "Out in The Lancet Haematology DAC-VEN-PONATINIB in CML MBP by…
Sep 24, 2024, 11:34 | Blog
Rahul Banerjee: A picture worth a thousand words
Rahul Banerjee shared a post on X, about recent paper published in The Lancet Haematology:…
Sep 4, 2024, 06:48 | Blog
Effects of persistent exposure to low doses of ionising radiation - IARC
IARC - International Agency for Research on Cancer shared on LinkedIn: "New article from IARC…
Jul 31, 2024, 21:38 | Blog
Rahul Banerjee: Dual-targeting CAR-T in Multiple Myeloma same week
Rahul Banerjee, Assistant Professor at UW Medicine, shared a posts on X: "Research letter in JAMA Oncolgy -…
Jul 3, 2024, 02:35 | Insight
Rahul Banerjee: Fascinating small Ph2 trial on relapsed or refractory multiple myeloma
Rahul Banerjee, Assistant Professor at UW Medicine, made the following post on X: “Absolutely abscopal…
Jun 19, 2024, 11:49 | Blog
Toby Eyre: Epcoritamab monotherapy in patients with lymphoma by Kim M Linton et al
Toby Eyre, CLL specialist at Oxford University Hospitals, shared on X: "Epcoritamab monotherapy in patients with…
May 9, 2024, 10:46 | Insight
Kai Rejeski: All that we currently know and understand about CAR-T related cytopenias
Kai Rejeski, Visiting investigator at Memorial Sloan Kettering Cancer Center, shared on X: "Check out…
Feb 15, 2024, 18:42 | Drugs
Alex Bataller: Phase 1/2 trial results of oral decitabine/cedazuridine with venetoclax in higher risk MDS and CMML
Alex Bataller, Leukemia fellow at Leukemia Department, MD Anderson Cancer Center (Houston, Texas), shared a…
Jan 30, 2024, 15:51 | Insight
Manni Mohyuddin: It is often well known that the control arm is inferior prior to a single patient being enrolled on trial!
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, shared on X/Twitter:…
Nov 20, 2023, 03:53 | Insight
Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3
Andres Gomez, Associate Professor at the Autonomous University of Nuevo León, Monterrey, Mexico, posted on…
Nov 14, 2023, 01:06 | Blog
Fadi Haddad: P3 trial of DAC-10 vs 7+3 in older AML pts followed by ASCT
Fadi Haddad, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas…
Nov 4, 2023, 16:12 | Drugs
Vincent Rajkumar: How I treat newly diagnosed myeloma
Vincent Rajkumar, Editor-in-Chief of the Blood Cancer Journal, shared on Twitter: "How I treat newly…
Sep 5, 2023, 17:40 | Insight
Amar Kelkar: Despite no difference OS/EFS, authors conclude young patients benefit due to lower relapse rates. We're skeptical
Amar Kelkar, Physician at the Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard…
Sep 3, 2023, 17:31 | Insight
Jayastu Senapati: A small effort highlighting the challenges in the care of patients with AML in LMICs - The Lancet Haematology
Jayastu Senapati, a clinical fellow, at MD Anderson Cancer Center, recently tweeted: "A small effort…
All: 16 Posts: 1 - 100
Special Coverage